Overcome tumor relapse in CAR T cell therapy

• Cheng-Dong Huo ^[2] ; Jie Yang ^[1] ; Yan-Mei Gu ^[2] ; Dai-Jun Wang ^[2] ; Xiao-Xia Zhang ; Yu-Min Li ^[2]
  1. [1] Gansu Provincial Hospital

     Gansu Provincial Hospital

     China

     
  2. [2] The Second Clinical Medical School of Lanzhou University, The Second Hospital of Lanzhou University, Lanzhou, Gansu Province, China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 10 (October), 2022, págs. 1833-1843
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Chimeric antigen receptor (CAR) T cell therapy is a novel therapeutic approach that uses gene editing techniques and lentiviral transduction to engineer T cells so that they can effectively kill tumors. However, CAR T cell therapy still has some drawbacks: many patients who received CAR T cell therapy and achieve remission, still had tumor relapse and treatment resistance, which may be due to tumor immune escape and CAR T cell dysfunction. To overcome tumor relapse, more researches are being done to optimize CAR T cell therapy to make it more precise and personalized, including screening for more specific tumor antigens, developing novel CAR T cells, and combinatorial treatment approaches. In this review, we will discuss the mechanisms as well as the progress of research on overcoming plans.